Corporate Information

"Preparing for change before change beckons. Harnessing the power of innovative research. Providing high-quality medicines for a healthier world. This is our world at Wockhardt."

Wockhardt has created a strong and growing presence in pharmaceutical formulations, biopharmaceuticals, nutrition products, vaccines and active pharmaceutical ingredients (API's) sold in over 90 countries across the globe. All of Wockhardt's manufacturing facilities have the approval of major regulatory bodies, including the US FDA and the UK MHRA.

Please visit our corporate website at www.wockhardt.com for more information.

Management Team

"An experienced leadership team of industry professionals committed to serving the US healthcare marketplace with high-quality products and innovative treatment solutions and education."

USA History

"Wockhardt has a strong track record of acquisition management, forming strategic alliances and developing a world-class organization and culture."

Wockhardt Limited created its US subsidiary Wockhardt USA in early 2004 with a modest portfolio of three FDA-approved generic products.  Since inception, Wockhardt’s business has steadily increased in the US.  Only four years later, Wockhardt USA now has a product line of 24 oral solid and injectable products.

Chicago-based Morton Grove Pharmaceuticals was acquired by Wockhardt Limited in October 2007 in order to expand Wockhardt’s product line in the US.  Since 1995, Morton Grove has been a leading manufacturer and marketer of oral liquid and topical pharmaceuticals.  The company's core products are manufactured in its 125,000 square foot, state-of-the-art facility.

To see USA highlights, click here.

Wockhardt acquires Morton Grove in the US